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Original article
Hypertension affects approximately 30% of all US adults1 
and is the leading risk factor for cardiovascular morbidity 
and mortality.2 Although antihypertensive medication is the 
mainstay of blood pressure (BP) control, dietary sodium 
restriction has been widely recommended as a public health 
measure for both prevention and treatment of hyperten-
sion.3 Sodium restriction has been found to lower mean 
BP,4–6 with a recent Cochrane review indicating an average 
systolic BP (SBP) reduction of 3.5% in hypertensive patients 
when sodium intake was reduced by 125 mmol/day.7
At the same time, controversy exists on whether this 
sodium–BP effect actually translates to cardioprevention 
because intensive sodium restriction may have adverse 
effects on insulin resistance, triglycerides, and sympathetic 
nervous system activation.7,8 Studies directly examining the 
association between sodium intake and cardiovascular out-
comes have produced conflicting results, with some finding 
a direct association, some showing an inverse or J-shaped 
curve, and others finding no relation to cardiovascular dis-
ease mortality. The lack of a consistent association is high-
lighted by the recent Institute of Medicine report,9 which 
concluded that the available data preclude a recommenda-
tion to restrict sodium to <2,300 mg per day, as well as a 
recent meta-analysis demonstrating no association between 
reduced sodium intake and cardiovascular mortality despite 
a significant reduction in BP.10 Average sodium intakes vary 
widely across geographic locales, and differences among the 
populations studied may partially account for the seem-
ingly inconsistent results.11–32 This variation underscores the 
importance of population-specific studies.
In the United States, an adverse association of lower 
sodium intake with cardiovascular outcomes in a group of 
healthy hypertensive patients was reported in 1995. During 
an average of 3.8  years of follow-up, with a mean sodium 
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background
Although higher sodium intake is known to increase blood pressure, its 
association with cardiovascular mortality is less established. We exam-
ined the association of baseline sodium intake in a hypertensive cohort 
with all-cause and cardiovascular mortality over a mean follow-up of 
18.6 years.
methods
Three thousand five hundred five subjects were participants in a work-
site hypertension program. Sodium intake was estimated by 24-hour 
urine excretion. Mortality data were obtained from the US National 
Death Index. Unadjusted and multivariable-adjusted associations 
between sodium quartiles (quartile I (QI) to quartile IV (QIV)) and mor-
tality were assessed using Cox models.
results
Estimated mean ± SD sodium intake was 130 ± 69  mmol overall 
(55 ± 20 mmol in QI; 220 ± 56 mmol in QIV). Baseline systolic blood pres-
sure did not vary significantly between groups. Last available mean 
systolic blood pressure was highest in QI and lowest in QIV (137 ± 16 
vs. 134 ± 14 mm Hg; P  =  0.009). Overall there were 1,013 deaths (399 
cardiovascular). Unadjusted models exhibited significant inverse rela-
tionships between sodium and mortality outcomes. In adjusted mod-
els, sodium intake was not significantly associated with cardiovascular 
mortality (QI vs. QIV: hazard ratio (HR)  =  1.00; 95% confidence inter-
val (CI)  =  0.71–1.42; P  =  0.99). A  borderline significant direct associa-
tion with all-cause mortality was observed (QI vs. QIV: HR = 0.81; 95% 
CI = 0.66–1.00; P = 0.05) driven partly by noncardiovascular deaths.
conclusions
Our study found no significant association between sodium intake and 
cardiovascular outcomes, although a significant association with all-
cause mortality was observed. Although these findings suggest that 
sodium may not have a strong relationship with cardiovascular mortal-
ity, the inconsistent results cast doubt on whether a single measure-
ment can reliably predict mortality over a prolonged follow-up period.
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intake of 115 mmol, an inverse association with myocardial 
infarction (MI) was found.13 Our study describes the asso-
ciation of sodium intake with long-term all-cause and car-
diovascular mortality in this same cohort, now after nearly 
20 years of mean follow-up. This represents the longest fol-
low-up to date of baseline sodium excretion with mortality 
outcomes in hypertensive subjects.
METHODS
Study population
Patient recruitment methods have been described in detail 
elsewhere.33 Briefly, participants were individuals in a union-
sponsored, worksite hypertension program in New York City 
between 1978 and 1999. Entry criteria were an SBP ≥140 mm 
Hg (≥160 mm Hg before Joint National Committee 5), dias-
tolic BP (DBP) ≥90 mm Hg (≥95 mm Hg before Joint National 
Committee 5), or being on antihypertensive medication at 
the time of screening. After a medication washout period of 
3–4 weeks, a pretreatment study visit was performed. Three 
BP readings using a standard sphygmomanometer were 
taken, the last 2 of which were averaged for the visit reading. 
Laboratory analyses, including a 24-hour urine collection, 
were obtained at this visit. Although some laboratory testing 
was repeated at multiple points throughout follow-up, a urine 
collection was obtained only at baseline. Antihypertensive 
medications were prescribed as needed throughout the period 
of study participation. Medication prescription generally fol-
lowed Joint National Committee recommendations but was 
ultimately at the discretion of the physician, and from 1981 
to 1988, a subset of participants were randomly assigned to 
initial monotherapy of a diuretic or β-blocker.34 The last BP 
available was the last one recorded in the program.
Sodium measurement
A single 24-hour urine collection was obtained at the pre-
treatment study visit after the medication washout period. 
Subjects were instructed to follow their usual diet while avoid-
ing “excessively salty foods” for a period of 4–5 days preced-
ing the collection. The first void on the day of collection was 
discarded, and that of the following day was included in the 
measurement. Urine sodium was analyzed using a flame pho-
tometer (Instrumentation Laboratories, Bedford, MA, through 
1985), or ion-selective electrode (Beckman Astra, Brea, CA).13
Endpoints
Mortality data were obtained using National Death Index 
Plus and the Social Security Administration Death Master 
File. Mortality data were available through August 2009. 
Causes of death were categorized as coronary artery disease, 
including MI, ischemic heart disease, heart failure, and 
hypertensive heart disease (International Classification of 
Diseases, Ninth Revision (ICD-9): 402.9, 410–414.9, 427.5, 
429.2; International Classification of Diseases, Tenth Revision 
(ICD-10): I10–11.9, I13–I13.2, I20–I25.9, I46–I46.9); 
stroke (ICD-9: 434–434.9, 436–438.9; ICD-10: I61–I64.9); 
other cardiac causes (ICD-9: 390–459.9; ICD-10: I00–I99 
excluding those listed above); noncardiovascular causes, of 
which approximately 50% were cancer deaths (ICD-9: 140–
239; ICD-10: C00–D49); and cause of death unknown.35 
Unknown causes of death primarily consisted of those after 
2007, for which National Death Index ICD codes were not 
available. For outcome analysis, all cardiovascular mortal-
ity included death from coronary artery disease, stroke, 
and other cardiac causes. Limited cardiovascular mortality 
included only MI, ischemic or hypertensive heart disease, 
and heart failure, while excluding stroke and other cardiac 
causes, which were thought could differ in their relationship 
to sodium intake.
Statistical analysis
Values of 24-hour urine sodium were divided into sex-
specific quartiles, in which men and women were first 
divided into respective sodium quartiles, which were then 
combined, such that quartile I  (QI) contained the lowest 
quartile, respectively, of male values and female values, and 
so on. Units of urinary sodium were expressed in milli-
moles per 24 hours, with 1 mmol equal to 23 mg of sodium. 
Potential covariables and confounders were identified based 
on prior literature and biologic plausibility, and bivariable 
analyses were analyzed using analysis of variance or χ2 test-
ing as appropriate. Estimated glomerular filtration rate was 
measured using the Chronic Kidney Disease—Epidemiology 
formula.36 Continuous variables were log-transformed as 
needed to meet normality assumptions. Unadjusted and 
adjusted Cox proportional hazards were performed to 
examine the association of 24-hour urine sodium quartiles 
with mortality. Quartile IV (QIV) was used as the reference 
category in all models. A backwards elimination approach 
was used to arrive at reduced models, and variables found 
to be independent predictors at P  <  0.05 or that showed 
evidence of confounding the sodium association (change 
in hazard ratio (HR) for sodium of >10%) were retained in 
the model. In addition, age, race, sex, and body mass index 
were forced into all models. A forward stepping procedure 
was then applied to all variables that remained in the final 
model to assess for confounding. Interactions were checked 
using product terms. The proportional hazard assump-
tion was tested using STATA’s goodness-of-fit command, 
which examines the proportional hazards assumption for 
the overall model as well as for each individual variable as 
a time-varying covariable. Models were analyzed using all-
cause mortality, all cardiovascular mortality, and limited 
cardiovascular mortality as outcomes. Subset analyses were 
performed as described below. All analyses were performed 
using STATA 12.0 (STATA Corp, College Station, TX).
RESULTS
Baseline characteristics
Three thousand five hundred five study participants com-
pleted a 24-hour urine collection. Baseline characteristics of 
participants are shown in Table  1. The overall mean ± SD 
urinary sodium in our cohort was 130 ± 69 mmol (equiva-
lent to approximately 3 grams of sodium, or 7.5 grams of 
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salt), with a mean ± SD of 55 ± 20 mmol in the lowest quar-
tile vs. 221 ± 56 mmol in the highest quartile.
The study population was 64% men, with a mean ± SD age 
of 52 ± 10 years. Those in the highest sodium quartile were 
significantly younger than those in the lowest, although 
the mean age at baseline differed by only 2 years. Blacks, 
whites, and Hispanics each accounted for approximately 
one-third of the study population and were represented 
fairly evenly across all sodium quartiles. No significant dif-
ferences were seen across quartiles with regards to base-
line history of cardiovascular disease, diabetes, or chronic 
kidney disease. Baseline body mass index was significantly 
associated with sodium quartiles. There was no significant 
difference in baseline SBP, and although differences in 
baseline DBP were statistically significant (P = 0.008), the 
mean absolute difference between QI and QIV was small. 
Both urine potassium and urine volume were higher in the 
higher urinary sodium quartiles, suggesting higher total 
daily food intakes.
Follow-up characteristics
The average in-program time was 6.5 ± 4.4  years, with 
no significant difference between the sodium quartiles 
(P  =  0.63). Weight increased over the course of the study, 
with an average participant weight gain of 0.9 ± 6.7 kg 
between the first and last visits. Those in QIV were signifi-
cantly heavier than those in QI at last follow-up (86.5 ± 17.2 
vs. 77.7 ± 13.5 kg; P  <  0.001), however this difference was 
similar in magnitude to that at the start of the study.
Last observed creatinine, uric acid, hematocrit (Hct), 
blood sugar, and cholesterol did not differ significantly 
across sodium quartiles (data not shown). Only baseline 
measurements of urine sodium were obtained during the 
study, and no repeat measurements were available.
Mean BP decreased in all sodium quartiles throughout 
the duration of the study period, with an overall average final 
SBP of 136 ± 15 mm Hg and DBP of 84 ± 9 mm Hg. Last avail-
able follow-up values revealed the SBP to be highest in QI, 
Table 1. Baseline characteristics by sex-specific urinary sodium quartiles
Characteristic Urine  
sodium, mmol/24 h
Quartile I  
(n = 890) 55 ± 20
Quartile II  
(n = 876) 102 ± 17
Quartile III  
(n = 865) 143 ± 20
Quartile IV  
(n = 874) 221 ± 56 P value
Male sex 564 (63.4) 567 (64.7) 552 (63.8) 559 (64.0) 0.95
Age, y 53.7 ± 9.8 53.1 ± 9.2 51.5 ± 9.9 51.0 ± 9.2 <0.0001
Race
 Black 269 (30.2) 257 (30.5) 264 (30.5) 250 (28.6) 0.04
 White 282 (31.7) 295 (33.7) 274 (31.7) 256 (29.3)
 Hispanic 300 (33.7) 305 (34.8) 309 (35.7) 335 (38.3)
 Other 39 (4.4) 18 (2.1) 18 (2.1) 33 (3.8)
History
 MI 10 (1.1) 4 (0.5) 9 (1.0) 13 (1.5) 0.20
 Stroke 8 (0.9) 5 (0.6) 8 (0.9) 6 (0.7) 0.80
 Angina 30 (3.4) 29 (3.3) 32 (3.7) 27 (3.1) 0.92
 DM 36 (4.0) 55 (6.3) 48 (5.6) 52 (6.0) 0.17
 CKD 13 (1.5) 12 (1.4) 10 (1.2) 19 (2.2) 0.34
Antihypertensive drug use 329 (37.0) 349 (39.9) 347 (40.2) 307 (35.2) 0.27
Smoking 187 (21.0) 179 (20.4) 165 (19.1) 144 (16.5) 0.08
BMI, kg/m2 27.4 ± 4.1 27.8 ± 4.1 28.9 ± 4.5 30.0 ± 4.9 <0.0001
SBP, mm Hg 146.4 ± 18.5 145.3 ± 17.7 145.2 ± 16.5 145.8 ± 16.3 0.41
DBP, mm Hg 93.6 ± 10.0 93.9 ± 9.7 94.1 ± 9.4 95.1 ± 9.6 0.01
Hematocrit, mg/dl 43.7 ± 4.0 43.5 ± 4.0 43.7 ± 4.1 43.4 ± 4.0 0.37
Cholesterol, mg/dl 223.2 ± 45.2 222.0 ± 43.5 219.4 ± 42.4 218.7 ± 39.8 0.09
Uric acid, mg/dl 5.9 ± 1.5 5.7 ± 1.4 5.7 ± 1.4 5.7 ± 1.4 0.004
Plasma renin activity, ng/ml/h 1.7 (0.64–3.4) 1.4 (0.56–2.6) 1.4 (0.54–2.6) 1.2 (0.49–2.4) 0.0001
eGFR, ml/min/1.73 m2 76.5 ± 16.5 77.9 ± 16.6 78.5 ± 16.4 80.6 ± 16.1 <0.0001
Urine potassium, mmol/24 h 49.5 (25.9) 58.0 (36.8) 60.6 (23.5) 69.9 (27.0) <0.0001
Urine volume, L 1.2 ± 0.6 1.3 ± 0.6 1.5 ± 0.5 1.7 ± 0.6 <0.0001
Results are reported as mean ± SD, median (nterquartile range), or frequency (%).
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated 
glomerular filtration rate; MI, myocardial infarction; SBP, systolic blood pressure.
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with no significant difference in DBP. Table 2 illustrates the 
changes in BP measurements throughout the study period.
At the time of the last program visit, approximately 80% 
of study participants were being prescribed at least 1 anti-
hypertensive medication, with 33% having been prescribed 
≥3 drugs. There were no significant differences in the num-
ber of antihypertensives prescribed at the time of last pro-
gram visit (mean in Q1 vs. Q4  =  1.65 ± 1.1 vs. 1.72 ± 1.2; 
P = 0.51).
Sodium and mortality outcomes
The overall mean length of follow-up, measured as the 
time from initial intake to death or last known alive, was 
18.6 years. Overall, there were 1,013 deaths, with 287 total 
deaths in QI vs. 216 in QIV. Of the total deaths, 399 were due 
to cardiovascular causes, with 128 cardiovascular deaths in 
QI vs. 78 in QIV. Most deaths occurred among patients after 
they were no longer in the worksite program. Approximately 
half of noncardiovascular deaths for which the cause was 
known were due to cancer. Figure 1 shows details of non-
cardiovascular causes of death. In unadjusted analysis, lower 
sodium intake was consistently associated with a higher 
mortality across all outcomes measured. Figure  2 shows 
crude mortality data as well as unadjusted HRs for all-cause 
and cardiovascular mortality.
Table  3 shows the results of multivariable Cox propor-
tional hazards modeling for all-cause, cardiovascular, lim-
ited cardiovascular, and noncardiovascular mortality, and a 
survival curve for all cardiovascular mortality is shown in 
Figure 3. Although a borderline direct association between 
sodium and all-cause mortality was found, no association 
between sodium and cardiovascular death was observed. 
When cardiovascular deaths were excluded from the model, 
results became highly significant QI vs. QIV: HR  =  0.57; 
P = 0.001), suggesting the overall significance with all-cause 
mortality was at least partially driven by noncardiovascular 
events. When looking exclusively at cardiovascular deaths 
in a noncompeting risk model, urinary sodium was not 
significantly associated with all cardiovascular or limited 
cardiovascular mortality (QI vs. QIV: HR = 0.86, P = 0.38; 
HR = 0.79, P = 0.20, respectively). In a post hoc power analy-
sis, we had >80% power to observe a true, independent pop-
ulation HR for cardiovascular disease mortality of sodium 
Table 2. Relationship of blood pressure to sodium quartiles
Blood pressure parameters Quartile I Quartile II Quartile III Quartile IV P value
Initial
Systolic 146.4 ± 18.5 145.2 ± 17.7 145.1 ± 16.5 145.8 ± 16.3 0.41
Diastolic 93.6 ± 10.0 93.9 ± 9.7 94.1 ± 9.4 95.1 ± 9.6 0.008
No. of hypertensives (%) 745 (84) 727 (84) 744 (87) 756 (87) 0.31
First follow-up
 Systolic 141.6 ± 15.9 142.6 ± 16.1 141.2 ± 16.9 140.9 ± 15.8 0.26
 Diastolic 89.6 ± 8.8 89.5 ± 9.4 90.0 ± 9.4 90.0 ± 8.5 0.44
Final In-Program
 Systolic 136.7 ± 15.8 136.2 ± 15.1 135.1 ± 16.0 134.3 ± 14.5 0.006
 Diastolic 83.8 ± 9.7 84.1 ± 8.9 84.0 ± 9.5 84.4 ± 9.1 0.57
No. on medication (%) 689 (77) 668 (76) 655 (76) 682 (78) 0.65
Blood pressure is expressed in mm Hg. Data are mean ± SD unless otherwise noted.
Figure 1. Noncardiovascular causes of death (excluding unknown). Abbreviation: GI, gastrointestinal.
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QI to QIV ≤0.85 or ≥1.17 and ≥95% power to detect a true 
HR ≤0.80 or ≥1.23.
In examining the potential cause for the difference 
between adjusted and unadjusted analysis, a forward mod-
eling technique was used to assess confounding in all vari-
ables that remained in the final models. Baseline age was 
significantly higher in the lowest sodium quartile (53.7 years 
in QI vs. 51  years in QIV), and adjusting for this variable 
alone strongly altered the associations seen in the unad-
justed analyses. Other variables tested were not shown to 
substantially confound this association.
The proportional hazard assumption was tested and was 
not violated for any of the final models. To assess the pos-
sibility of a J- or U-shaped relation, models were retested 
using quartile II (QII) as a reference quartile. No significant 
association was found for other quartiles vs. QII for any 
mortality outcome tested (overall, cardiovascular, limited 
cardiovascular mortality).
Sensitivity analyses
In addition to quartile analysis, sodium was analyzed as 
a continuous variable, with similar results. To account for 
possible problems with 24-hour urine collections, subset 
analyses excluding the top and bottom 1% of urinary sodium 
values and excluding those whose calculated creatinine 
clearance did not fall within ±35% of estimated glomeru-
lar filtration rate were performed and did not substantially 
change our results. In light of the study findings of Geleijnse 
et al.,22 urine sodium/potassium ratio was also examined and 
was not found to be a significant independent predictor of 
mortality. Models excluding SBP (due to its potential media-
tion) and models excluding participants with a baseline BP 
<140/90 mm Hg after the medication washout period, who 
may not have been truly hypertensive at baseline, similarly 
did not affect results.
DiSCUSSiON
We found a borderline significant association of sodium 
intake with all-cause mortality, a highly significant asso-
ciation with non–cardiovascular disease mortality, and no 
significant association with cardiovascular outcomes. These 
multivariable-adjusted findings were in contrast to unad-
justed analyses, in which significant inverse associations 
were seen for both all-cause and cardiovascular mortality. 
The degree of discrepancy between adjusted and unadjusted 
analysis was largely a result of the baseline age difference 
between the quartiles, even though the difference in mean 
age was small.
This may also explain the discrepant findings with the 
earlier report of this cohort,13 which found a significantly 
greater risk of MI in men with lower sodium intake. It is 
important to note that the earlier study had many more 
morbid events than fatalities (221 vs. 61, respectively), and 
the effect of age on morbidity may be less prominent than 
that on death. Unfortunately, long-term morbidity data 
were not available in our study. Furthermore, the follow-up 
time in the previous study was substantially shorter, with a 
mean of 3.8 years. On a population level, sodium intake has 
been shown to be very consistent over prolonged periods 
of time,37 but it is unclear whether this is also applicable to 
individuals.
Another possible explanation for the lack of significant 
association over the long term is the effect of “regression 
dilution bias,”38 in which, due to a combination of measure-
ment error and within-individual variance, single measure-
ments of a baseline characteristic tend to underestimate the 
Figure  2. Raw mortality data by sodium quartiles. All-cause mortality (QI vs. QIV: unadjusted hazard ratio (HR)  =  1.25; 95% confidence interval 
(CI) = 1.05–1.49; P = 0.01); all cardiovascular mortality (QI vs. QIV: HR = 1.61; 95% CI = 1.21–2.13; P = 0.001); limited cardiovascular mortality (QI vs. QIV: 
HR = 1.49; 95% CI = 1.08–2.05; P = 0.01); noncardiovascular mortality (QI vs. QIV: HR = 1.02; 95% CI = 0.77–1.35; P = 0.87).
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strength of association with an outcome over time. Thus it 
remains possible that with multiple measurements a signifi-
cant association could have been seen, although the magni-
tude or even direction of such a potential association cannot 
be estimated without making assumptions that cannot be 
tested.
Finally, during the study the majority of participants 
were placed on antihypertensives, with similar declines in 
BP throughout the study period. Although it is possible that 
attention to BP measurements may have altered participants’ 
sodium intake, undermining the ability to determine an 
association, without repeat measurements it is impossible 
to know whether changes in sodium intake differentially 
affected those in each quartile.
Despite the nonsignificant cardiovascular findings, a 
borderline significant direct association with all-cause 
mortality and a strongly significant association with non-
cardiovascular mortality remain and must be explained. 
Because of the diverse causes of noncardiovascular death, of 
which 50% were cancers, and without a mechanism linking 
sodium intake to these various causes, it seems more likely 
that this represents either a chance finding or latent con-
founding rather than a causative contribution of sodium to 
mortality. Furthermore, analysis of in-program follow-up 
data revealed that final in-program SBP was highest in the 
lowest sodium quartile. This finding contradicts the pre-
sumed mechanism that sodium increases risk of mortal-
ity by increasing BP. One potential explanation for all of 
these findings together is that sodium intake, although not 
the true cause of the association with mortality, is a marker 
of overall health behaviors, and that those with the lowest 
sodium intakes may have been practicing healthier habits 
overall.
Strengths of this study include the long duration of 
follow-up and the estimation of sodium intake by urinary 
excretion, as opposed to questionnaire or recall methods, 
which may be less accurate.39 Other strengths include 
the use of a medication “washout” period, ensuring that 
baseline sodium measurements were not affected by medi-
cation use, and the worksite program design, in which 
participants were essentially healthy at entry, reducing 
concern for reverse causality.
A possible limitation of the study is the instruction 
to avoid “excessively salty food” in the days before the 
collection, as patients may have reduced their normal 
sodium intake, thereby introducing bias. It is important 
to note that the study period predated the mandated use 
of nutritional food labeling, therefore attempts to lower 
sodium intake over a few days may not have been as easily 
achieved as is currently possible.40 If, however, behavio-
ral changes did occur, this may have similarly affected all 
quartiles. Although a differential bias affecting primar-
ily those in the higher sodium quartiles is possible, it 
would be difficult to assess this in the absence of follow-
up sodium measurements, which is a major limitation of 
the study. Although a large study of temporal trends in 
sodium intake in the United States found no significant 
change over a 40-year period,37 these studies looked at 
a population level, and on the individual level, intakes 
may have varied substantially. Finally, the healthy worker 
effect, participation in an intensive worksite hypertension 
program, and lack of knowledge of change in hyperten-
sive treatment after the end of program participation may 
reduce the generalizability of our findings.
Taken together, our results indicate that the association 
of sodium intake, measured at baseline, is not significantly 
associated with long-term cardiovascular outcomes. If such 
an association does exist in this population, our data suggest 
it is likely to be modest and muted by intervening factors 
over the prolonged period of observation. The association 
with all-cause mortality found in our study is of borderline 
significance, driven in part by noncardiovascular events, 
and in the absence of a proposed mechanism of causality 
may be a chance association. Further studies with repeated 
assessments of sodium excretion may more clearly define 
the long-term association between sodium intake and mor-
tality outcomes.
Table 3. Adjusted hazard ratios for sodium quartiles with mortality 
outcomes, using quartile IV as reference
Mortality outcome Hazard ratio (95% CI) P value
All-cause mortalitya(n = 3,052)
 QI 0.81 (0.66–1.00) 0.05
 QII 0.90 (0.73–1.10) 0.31
 QIII 0.88 (0.71–1.09) 0.23
All cardiovascular mortalityb
 QI 1.00 (0.71–1.42) 0.99
 QII 0.96 (0.68–1.36) 0.82
 QIII 1.06 (0.75–1.49) 0.74
Limited cardiovascular mortalityc
 QI 0.93 (0.63–1.39) 0.73
 QII 0.82 (0.55–1.22) 0.34
 QIII 1.06 (0.73–1.55) 0.74
Noncardiovascular mortalityd
 QI 0.57 (0.41–0.80) 0.001
 QII 0.85 (0.63–1.16) 0.31
 QIII 0.80 (0.59–1.10) 0.18
All covariables listed are those at baseline. Backwards elimination 
approach was used to arrive at all final models.
Abbreviations: QI, quartile I; QII, quartile II; QIII, quartile III.
aAdjusted for age, sex, race, body mass index (BMI), systolic 
blood pressure (SBP), estimated glomerular filtration rate (eGFR), 
urine potassium, hematocrit, HxDM, Hx smoking, history of baseline 
left ventricular hypertrophy (Hx baseline LVH).
bAdjusted for age, sex, race, BMI, SBP, eGFR, urine potassium, 
hematocrit, plasma renin activity, HxDM, Hx smoking, history of 
baseline left ventricular hypertrophy.
cAdjusted for age, sex, race, BMI, SBP, urine creatinine, plasma 
renin activity, HxDM, Hx smoking, history of baseline left ventricular 
hypertrophy.
dAdjusted for age, sex, race, BMI, SBP, hematocrit, urine potas-
sium, HxDM, Hx smoking. Abbreviations: Hx smoking, history of 
smoking; HxDM, history of diabetes.
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